Autonomix Medical Common StockNASDAQ: AMIX

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company's ongoing human clinical trial

Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has received Ethics Committee approval of the protocol amendment for its ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. The primary objective of the PoC human clinical trial is to successfully ablate relevant nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region.

Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system

Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass

Live webcast presentation on Wednesday, March 20 th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced today that Lori Bisson, Chief Executive Officer of Autonomix will present at the Benzinga Virtual Healthcare Summit 2024 on Wednesday, March 20, 2024 at 11:50 AM ET. Benzinga's Virtual Healthcare Summit is a virtual event where the brightest minds in healthcare, influential companies, analysts, and thought leaders converge to shape the future of health.

Webcast presentation on Wednesday, February 14th at 10:30 AM EST THE WOODLANDS, TX / ACCESSWIRE / February 9, 2024 / Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will present at Integrous Communications' Big Hearts, Big Ideas Virtual Investor Conference on Wednesday, February 14, 2024 at 10:30 AM EST. In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.